Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Conditions

Multiple Sclerosis 2Carcinoma in Situ 2Sarcoma, Kaposi 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis, Chronic Progressive 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Magnetic Resonance Imaging 2Interferon beta-1b 2Electrocardiography 2Diphenhydramine 2Acetaminophen 2valrubicin 1pembrolizumab 1fludarabine phosphate 1fludarabine 1durvalumab 1dodecyl maltoside 1apaziquone 1aldesleukin 1Tomography, X-Ray Computed 1Respiratory Function Tests 1Proflavine 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Nicotine Replacement Therapy 1Meperidine 1Mastectomy, Subcutaneous 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1Imiquimod 1Hydroxyzine 1Histamine Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma in Situ × Interferon beta-1b × Clear all
NCT02486640 2023-07-24

BETAPREDICT

Bayer

Completed
162 enrolled

Carcinoma in Situ, Multiple Sclerosis

NCT03134573 2019-03-26

PROmyBETAapp

Bayer

Completed
96 enrolled

Carcinoma in Situ, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡